Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 41Gastrointestinal 37Thoracic 18Gynecologic 14CNS 14Genitourinary 8Breast 7Sarcoma 4Head & Neck 4Lymphoid 3Myeloid 2Other hematologic neoplasm 1NET 1Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Neuroendocrine Tumors 5Carcinoma, Neuroendocrine 5Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Somatostatinoma 2Neoplasm Metastasis 2Insulinoma 2Glucagonoma 2Gastrinoma 2Carcinoma, Islet Cell 2Carcinoid Tumor 2Adenoma, Islet Cell 2Vipoma 1Sarcoma 1Pancreatic Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Metastatic Gastrointestinal Carcinoid Tumor 1Mesothelioma, Malignant 1Lymphoma 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma 1Adrenocortical Carcinoma 1Adenocarcinoma, Mucinous 1

Interventions

Everolimus 6Sunitinib 4Octreotide 4Leucovorin 4dabrafenib 3Fluorouracil 33-Iodobenzylguanidine 3trametinib 2selpercatinib 2lutetium Lu 177 dotatate 2avelumab 2alectinib 2PM 01183 2Oxaliplatin 2Irinotecan 2Fulvestrant 2Drug Therapy 2Doxorubicin 2Cisplatin 2trifluridine tipiracil drug combination 1tipifarnib 1telotristat ethyl 1surufatinib 1somapacitan 1ribociclib 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Bevacizumab × Endocrine × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡